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Because relatively little is known about cancer in African
patients with HIV infection, reliance is placed on North
American and European data, which have a bias to male
homosexual patients and intravenous drug users. These
patients have very different backgrounds, and therefore
differing rates of smoking, cardiac disease, rectal
carcinoma and exposure to other infections, population
longevity and access to health care"
related issues and affeer the peoples of this region in many
ways, not least of which is apathy among the medical
profession and the sense of hopelessness that envelops
both physicians and patients alike. These factors lead to
under-reporting, inadequate record keeping and
subsequent referral of HIV-infected patients with
malignant disease. The extent of the problem is therefore
vastly underestimated for many HIV-infected people, and
ideal management of opportunistic infections - let alone
management of their HIV with antiretrovirals and the
management of more serious or complex problems - is
unobtainable.
NON-AIDS-RELATED
lYPES OF CANCER IN PATIENTS WITH HIV
AIDS-RELATED
The incidence of some cancers is so much higher in
populations of patients with HIV infection that a causal
relationship is difficult to exclude. These cancers are
associated with declining immune function and are
considered to be AIDS-defining.' They are:
• Non-Hodgkin's lymphoma (NHL) (300 x for diffuse
large-cell and 14 x for low grade)
• Kaposi's sarcoma (KS) (86 x for males, 260 x for
females)
• Cancer of the cervix (CaCx) (9 xl.
These cancers have a more modest increase in
incidence but the risk is nonetheless increased, as
shown in studies that link the diagnosis of these
malignancies to the diagnosis of HIV by placing their
diagnosis to within 60 months on either side of the
diagnosis of AIDS.' They are:
HIV AND CANCER INCIDENCE IN SUB-SAHARAN
AFRICA
MANAGEMENT OF CANCER IN PATIENTS
WITH HIV
As the incidence of HIV increases in Africa the coincidental
infection of cancer patients will rise. Owing to the effects
of HIV on haemopoiesis and immune function, HIV
infection of patients with cancer poses management
difficulties for both the physician managing the cancer and
the physician managing the HIV infection. For most
cancers, the dose intensity (total dose over total time) of
the chemotherapy or radiotherapy is strongly associated
with response rates. This is even more noticeable in
haematological malignancies and cancers with curable
potential. Maintaining dose intensity in the presence of
HIV requires control of the HIV infection and frequently the
use of external growth factor support, especially in
intensive regimens. It is not usually appropriate to attempt
anything except palliative treatment if these resources are
not available
More conventionally we think of cancer in HIV as cancer as
a result of the HIV infection. This is well described as either
related to decreased immune surveillance, or secondary to
other infections that are uncontrolled in a hos' with a
compromised immune system. In addition to their unique
problems these patients suffer the same disadvantages as
discussed above in the cancer patient who is also co-
incidentally infected with HIV.
INTRODUCTION
This article will discuss the increased incidence of certain
malignancies in patients with HIV, as well as the unusual
'eatures of these malignancies in HIV-infected individuals.
In addition, some of the di'~culties experienced in the
management of these patients, their cancers and their HIV
infection will be explored.
It is estimated that over 25 million HIV-infected individuals
live in sub-Saharan Africa. Most countries in this region
have no effective strategies in place to combat the growth
in this epidemic, largely owing to a lack of political
commitment together with a lack of resources. These
factors are important because they extend beyond HIV-
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• Hodgkin's disease (8 xl
• Trachea, bronchus and lung (3 - 7 xl
• Mouth (2 xl
• Brain and central nervous system (3 x)
• Skin, excluding KS (7 xl
• Multiple myeloma (3 - 7 xl.
PATHOGENESIS OF HN-RELATED MAUGNANCIES
Epstein-Barr virus (EBVl is a herpesvirus and has been
shown to drive B-cell proliferation in many ways. This virus
is ubiquitous in Africa, and immune suppression creates an
environment that is permissive for its reactivation and
hence B-cell stimulation. Reduced immunity also creates
an environment that is rich in antigenic stimulation which
further drives the proliferation of B cells with their
associated immunoglobulin gene rearrangements, cell cycle
and apoptotic pathway activation, creating a permissive
milieu for genetic mutations. In addition, HIV itself has
been shown to stimulate an inappropriate humoral
immune response and this cytokine barrage further
stimulates B-cell proliferation. Immune dysregulation
contributes to the process and eventually decreased
cytotoxic cell function leads to a decrease in immune
surveillance, allowing malignant cells to escape detection
and a failure of cell-mediated immune destruction. Human
herpesvirus 8 (HHV8) has been shown to be causally linked
to the development of body cavity-based lymphomas.'
Many of these factors, particularly the permissive
environment, reactivation of dormant infections, and
decreased cytotoxic immune surveillance, are thought to
play a role in other cancers. In KS, HHV8 is causally related
to the pathogenesis of this malignancy. Human
papillomavirus [HPV) has been causally linked to carcinoma
of the cervix and carcinoma of the anus. In particular, the
AIDS-related malignancies have been shown to improve
with control of the patient's HIV infection by antiretrovirals
and subsequent immune reconstitution. Control of the
patient's HIV infection shouk: therefore be the first goal of
therapy in any patient suffering from one of these
malignancies.
PRINCIPlES OF MANAGEMENT
EFFECTS OF CHEMOTHERAPY AND RADIOTHERAPY
ON HAEMOPOIESIS AND IMMUNE FUNCTION
Therapy for malignancies is by nature cytotoxic and also
leads to varying degrees of immunosuppression. In
particular, the chemotherapy used in the management of
haematological malignancies is by the nature of its target
profoundly myelosuppressive and immunosuppressive.
Although some latitude may be used when ueating with
palliative intent, if the goal is cure, for optimal results these
regimens should be adhered to. In this scenario growth
factor support is frequently required to achieve optimal
scheduling.
In addition, intensive chemotherapy and radiotherapy
frequently lead to sub-optimal nutrition due to mucositis,
nausea, diarrhoea, oral thrush and reactivation of herpes.
Infections, including bacterial community-acquired
pneumonia and urinary tract infections, are increased as a
result of chemotherapy and radiotherapy. In the context of
HIV this increase in antigenic load and immune stimulation
will serve to aggravate the immune dysfunction. Repeated
admission to hospital also increases the risk of nosocomial
infections.
Direct tissue damage secondary to the cytotoxic effects of
chemo- and radiotherapy may in turn lead to multiple
organ dysfunction such as hepatitis, renal failure and
respiratory impairment. These conditions further
compromise the patient's ability to withstand infections or
tolerate other medications, including antibiotics and
antiretrovirals.
However, newer agents such as monoclonal antibodies,
biological response modifiers, antisense RNA and anti-
angiogenic drugs hold promise of enhanced efficacy with
reduced toxicity and would be useful in this setting'
EFFECT OF HIV ON HAEMOPOIESIS AND IMMUNE
FUNCTION
As patients progress to more advanced stages of HIV
infection and their viral load rises progressively, they
become more immune-compromised. Infection of bone
marrow stromal cells, microvascular endothelial cells and
macrophages leads to impaired haemopoiesis with
progressive cytopenias. Even before this becomes apparent
the marrow has a decreased capability to withstand
suppression, and patients generally have a poor tolerance
of cytotoxic therapies. This is immediately improved if the
rate of viral proliferation is con rolled, even if the CD4+
Iymphocyte count is not increased in the face of
chemotherapy.
In addition, the obvious susceptibility to infection is
synergistic with the immune suppression of cytotoxic
therapy. The HIV-positive patient undergoing treatment for
cancer is therefore at serious risk of fatal acute infection.
This must be carefully explained to the patient and the risk
weighed up against the potential benefit. There must be
resources available to manage iatrogenic complications,
and these must be in place before initiating therapy and
thus committing the patient and the health care system to
a course of action that cannot be sustained or completed.
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CURATIVE V. PALLIATIVE INTENT
Although NHL may be curable in these patients, they
should be carefully selected as the majority have very
aggressive disease. These patients therefore require
aggressive multi-agent chemotherapy with its attendant
risks. Frequently they need external growth factor support
to either maintain dose intensity or give support during
sepsis. Their disease presentation is often atypical, with
extranodal or central nervous system disease which may
require a multidisciplinary approach between the surgeon,
radiotherapist and oncologist. High-grade histological
subtypes predominate, and as mentioned earlier an
association with EBV and HHV8 infection is common. Sadly
only the best risk patients will tolerate these intensive
regimens, and the risk remains high. However, good durable
remissions are achieved in a significant number
(± 30%) of patients.
KS is often a fairly indolent malignancy, and response can
be achieved with control of the patien"s HIV infection
alone. This angiosarcoma has a propensity for the skin and
lymph nodes, causing unsightly and embarrassingly
characteristic lesions or lymphoedema. Local radiotherapy
can give excellent results in the majority of patients. The
addition of anthracycline chemotherapy can further
enhance these results to complete local responses in over
800/0 of patients. However, the disease is usually
progressive and will ultimately involve the lungs, gastro-
intestinal tract and other organs, causing death. This AIDS-
defining illness usually presents in earlier stages of immune
compromise (median CD4 Iymphocyte count 300/ml), and
as such these patients tolerate chemotherapy reasonably
well. The sarcoma responds well to anthracycline-
containing regimens, with good responses in about 40% of
patients. Liposomal daunorubicin combinations have the
same results as single agents (or better ones) and are very
well tolerated, with little haemopoietic or other toxicities.
Koposi's sarcoma with chylous pleural effusion secondary to
lymph node obstruction.
undergo
For most patients with cancer and HIV, palliation is the best
option. Palliation does not mean automatically giving up
on the cancer; the patient may still benefit from its
appropriate local or systemic management. However, there
is a group of patients who have potentially curable
malignancies and should be evaluated for aggressive
therapy.
GOALS OF MANAGEMENT
The nucleoside analogues, in particular zidovudine (AlT),
are myelosuppressive and should be avoided or closely
monitored in patients receiving myelosuppressive
chemotherapy. In addition peripheral neuropathies are
relatively common with stavudine (D4T), didanosine [001)
and zalcitabine (DDC)' and these should be avoided or used
with caution in patients receiving the vinca-alkaloids
[vincristine, vinblastine) and the platinum-based drugs.
However, the use of antiretrovirals controls HIV replication,
leading to improvement not only in immune function, but
also in the haemopoietic reserve and the patient's ability to
tolerate cytotoxic therapy. Immune reconstitution may lead
to regression of the tumour and an improved clinical
outcome.
Protease inhibitors, in particular ritonavir, have an effect on
drugs metabolised via the cytochrome P4S0 pathway and
may enhance toxicities of some chemotherapeutic agents
such as cyclophosphamide and anthracyclines at higher
doses.
ANTlRETROVIRAL THERAPIES HAVE MULTIPLE
TOXICITIES AND DRUG INTERACTIONS
A recent trial' showed a marked reduction in the incidence
of NHL in patients on highly active antiretroviral therapy
(HAART) compared with patients in the pre-HAART era.
This reduction was shown to result from fewer patients
with severe immune compromise. This shows that not only
is immune impairment necessary for the development of
the AIDS-related NHL, but controlling the HIV infection
leads to an improvement in the health of this patient
population.
Patients who have a better outcome are:
• those with localised cancers
• those with earlier-stage cancers
• the younger age group
• those with good performance status
• those with earlier stage of HIV disease
• those on antiretrovirals.
It is advisable that any patient who is to
aggressive cancer therapy should be on HAART.
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Most patients with HIV and cancer can benefit from the
management of their HIV. In addition, local therapies
(surgery and radiotherapy) can lead to a cure, and
frequently significant improvement in quality of life results.
If selection of patients is careful, results can be excellent
A multidisciplinary approach and co-operation between
the oncologist and the infectious diseases physician are
essential to optimise the outcome in these patients.
